JEVTANA KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JEVTANA KIT (JEVTANA KIT).
JEVTANA KIT contains cabazitaxel, a microtubule inhibitor that promotes tubulin assembly and stabilizes microtubules, leading to G2/M cell cycle arrest and apoptosis.
| Metabolism | Primarily metabolized by CYP3A4 (major) and CYP3A5 (minor) in the liver. Less than 20% excreted unchanged in urine. |
| Excretion | Primarily biliary/fecal: ~75% of dose recovered in feces as unchanged drug and metabolites; renal excretion accounts for <5% of the dose. |
| Half-life | Terminal elimination half-life is approximately 95 hours (range 34–266 hours), supporting a prolonged dosing interval of every 3 weeks. |
| Protein binding | Bound approximately 89–93% to plasma proteins, mainly albumin and α1-acid glycoprotein. |
| Volume of Distribution | Steady-state volume of distribution is large, approximately 1.8 L/kg (range 0.6–4.0 L/kg), indicating extensive extravascular distribution and tissue binding. |
| Bioavailability | Not applicable; Jevtana is administered only as an intravenous infusion. Oral bioavailability has not been studied. |
| Onset of Action | Not applicable; clinical effect (antitumor activity) is delayed and not typically defined by an onset time. For pharmacokinetic parameters, absorption after IV administration is immediate. |
| Duration of Action | Duration of action is prolonged due to long half-life; clinical effects persist over the 3-week dosing cycle. Neutropenia nadir occurs at 7–10 days with recovery by day 21. |
60 mg/m² IV over 1 hour every 3 weeks in combination with oral prednisone 10 mg daily continuously.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended for severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Use caution and consider dose reduction to 40 mg/m² in moderate hepatic impairment (Child-Pugh class B). |
| Pediatric use | Safety and efficacy not established; no approved pediatric dosing. |
| Geriatric use | No specific geriatric dose adjustment; patients >65 years had more adverse reactions but similar efficacy. Monitor for increased toxicities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JEVTANA KIT (JEVTANA KIT).
| Breastfeeding | It is not known whether cabazitaxel is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during treatment and for at least 2 weeks after the last dose. No M/P ratio data available. |
| Teratogenic Risk | Pregnancy category D. Based on its mechanism of action (taxane antimicrotubule agent) and animal studies, JEVTANA (cabazitaxel) is expected to cause fetal harm when administered to a pregnant woman. In rats, cabazitaxel was embryotoxic and fetotoxic at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester exposure carries the highest risk of major malformations; second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and fetal/neonatal toxicity. |
■ FDA Black Box Warning
Severe hypersensitivity reactions, including anaphylaxis, can occur. Neutropenia, febrile neutropenia, and neutropenic infections have been reported.
| Serious Effects |
Hypersensitivity to cabazitaxel or polysorbate 80; baseline neutrophil count < 1,500 cells/mm³; severe hepatic impairment (Child-Pugh class C).
| Precautions | Neutropenia, febrile neutropenia, severe hypersensitivity, gastrointestinal toxicities (including diarrhea, nausea, vomiting, stomatitis), interstitial pneumonia, renal failure, hepatic impairment, and embryo-fetal toxicity. |
Loading safety data…
| Fetal Monitoring | Monitor complete blood counts (CBC) regularly due to myelosuppression (neutropenia, thrombocytopenia, anemia). Monitor for signs and symptoms of infections, bleeding, and hypersensitivity reactions. Assess hepatic function (AST, ALT, bilirubin) before and during therapy. Monitor renal function (serum creatinine) and electrolyte levels. During pregnancy, perform fetal ultrasound to assess growth and amniotic fluid volume; consider fetal echocardiography if exposure occurs in first trimester. |
| Fertility Effects | Cabazitaxel may impair fertility in males based on animal studies showing testicular atrophy and reduced spermatogenesis. In female rats, cabazitaxel caused disruption of estrous cycles and reduced fertility. The potential for reversible or permanent infertility in humans is unknown. Advise patients of the risk to reproductive capacity. |